We initially studied the impact of tofacitinib on intracellular pathways activated in human keratinocytes by proinflammatory cytokines with a pathogenic role in psoriasis, including IFN-γ, IL-22, TNF-α, and IL-17. This evidence concerns the gene IL22 and psoriasis.